

Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K

CALLISTO PHARMACEUTICALS INC
Form 8-K
July 01, 2003

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 30, 2003

Callisto Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware	333-63474	65-110840
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)

420 Lexington Avenue, Suite 601
New York, New York 10170
(Address of principal executive offices)

Registrant's telephone number, including area code: (212) 672-9190

(Former name or former address, if changed since last report)

Item 5 Other Events and Required FD Disclosure

On June 30, 2003, Callisto Pharmaceuticals, Inc. announced the appointment of new members of the Board of Directors and certain management changes in connection with the merger agreement with Synergy Pharmaceuticals Inc.

Item 7 - Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits

Exhibit No.	Description
-----	-----
99.1	Press Release of Callisto Pharmaceuticals, Inc. announcing appointment of new members of the Board of Directors and certain management changes in connection with the merger agreement with Synergy Pharmaceuticals Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereto duly authorized.

Dated: July 1, 2003

CALLISTO PHARMACEUTICALS, INC.

By: /s/ Gary S. Jacob

Gary S. Jacob, Ph.D.
Chief Executive Officer